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p75NTR antagonists attenuate photoreceptor cell loss in
murine models of retinitis pigmentosa
María Platón-Corchado1,3, Pablo F Barcelona2,3, Sean Jmaeff2, Miguel Marchena1, Alberto M Hernández-Pinto1,
Catalina Hernández-Sánchez1, H Uri Saragovi2,4 and Enrique J de la Rosa*,1,4
ProNGF signaling through p75NTR has been associated with neurodegenerative disorders. Retinitis pigmentosa (RP) comprises a
group of inherited retinal dystrophies that causes progressive photoreceptor cell degeneration and death, at a rate dependent on
the genetic mutation. There are more than 300 mutations causing RP, and this is a challenge to therapy. Our study was designed to
explore a common mechanism for p75NTR in the progression of RP, and assess its potential value as a therapeutic target. The
proNGF/p75NTR system is present in the dystrophic retina of the rd10 RP mouse model. Compared with wild-type (WT) retina, the
levels of unprocessed proNGF were increased in the rd10 retina at early degenerative stages, before the peak of photoreceptor cell
death. Conversely, processed NGF levels were similar in rd10 and WT retinas. ProNGF remained elevated throughout the period of
photoreceptor cell loss, correlating with increased expression of α2-macroglobulin, an inhibitor of proNGF processing. The
neuroprotective effect of blocking p75NTR was assessed in organotypic retinal cultures from rd10 and RhoPmouse models. Retinal
explants treated with p75NTR antagonists showed significantly reduced photoreceptor cell death, as determined by the terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay and by preservation of the thickness of the outer
nuclear layer (ONL), where photoreceptor nuclei are located. This effect was accompanied by decreased retinal-reactive gliosis
and reduced TNFα secretion. Use of p75NTR antagonist THX-B (1,3-diisopropyl-1-[2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-
purin-7-yl)-acetyl]-urea) in vivo in the rd10 and RhoP mouse models, by a single intravitreal or subconjunctival injection, afforded
neuroprotection to photoreceptor cells, with preservation of the ONL. This study demonstrates a role of the p75NTR/proNGF axis in
the progression of RP, and validates these proteins as therapeutic targets in two different RP models, suggesting utility
irrespective of etiology.
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Retinitis pigmentosa (RP) refers to a group of inherited retinal
dystrophies that are clinically similar despite arising from a
large set of genetic mutations (http://www.sph.uth.tmc.edu/
Retnet/disease.htm). These mutations usually trigger photo-
receptor cell degeneration and death, leading to visual
function decline and, eventually, blindness.1 While the time
of onset and the rate of neurodegeneration are specified by the
mutation, most, if not all, forms of RP share molecular and
cellular mechanisms that include inflammation, microglial
activation and reactive gliosis. These features are shared with
other retinal diseases without a pure genetic origin, such as
glaucoma, diabetic retinopathy and age-related macular
degeneration.2,3
Various therapeutic strategies for RP, including gene, cell
and regenerative therapies, as well as pharmacological
treatments, are gradually progressing from the animal models
to clinical trials4–6 and http://clinicaltrials.gov/ct2/results?
term= retinitis+pigmentosa. However, there is not yet any
approved treatment for the neurodegenerative component of
retinal diseases. The genetic complexity in the etiology of RP,
comprising more than 300 described mutations in over 50
different genes, calls for the development of treatments
targeting common mechanisms independently of the causa-
tive mutation. This would entail the detailed characterization of
the processes leading to retinal deterioration, as a strategy to
discover novel therapeutic targets.
As a monogenic genetic disease of high penetrance, a
variety of animal genetic models recapitulate the signs and
symptoms of human RP.4 A missense mutation in the Pde6b
gene causes blindness in the rd10mouse model of autosomal
recessive RP.7 The RhoP mouse model of autosomal
dominant RP carries the mutant human rhodopsin Pro347Ser
transgene.8 The course of the disease in these models
recapitulate human progression and allows for effective
experimental interventions.9–16 We used these independent
models of RP to study the involvement of the p75NTR/proNGF
axis in the course of disease.
ProNGF is the precursor of mature NGF. ProNGF and NGF
display opposite effects, depending on the receptor-complex
stimulated. Both bind p75NTR that mediates a neurotoxic
effect. Indeed, p75NTR activation is involved in several
neurodegenerative conditions.17,18 The deleterious signals
of p75NTR require an interacting protein sortilin, and are ligand
dependent and activated by proNGF (although some signals
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can also be ligand independent).18 Conversely, NGF also
binds the neuroprotective receptor Trk-A that can counter-
balance p75NTR. Other proneurotrophins also bind p75NTR,
although their functional impact is less characterized than in
the case of proNGF.18
In retinal neurodegeneration associated with glaucoma and
diabetic retinopathy, proNGF stimulates p75NTR-dependent
production and secretion of TNFα and α2-macroglobulin (α2M)
by activated glia.19–23 These are neurotoxic factors that trigger
neuronal death in a paracrine manner. In addition, neurotoxic
mechanisms are further promoted by α2M interacting with
amyloid,24 and by α2M stabilizing proNGF and enhancing
p75NTR activation.22
Hence, expression of proNGF, TNFα, α2M, sortilin, as well
as neuronal damage and glial activation, serve as markers of
p75NTR-mediated neurodegeneration in vivo. Here, we char-
acterize these components in the dystrophic rd10 and RhoP
retinas, as well as the use of p75NTR antagonists to reduce
neurotoxicity and delay neurodegeneration, both in retinal
explants and in vivo. This work validates inhibition of p75NTR
as a therapeutic target for treatment of many forms of RP.
Results
Previous findings demonstrate the involvement of the proNGF/
p75NTR system in optic nerve axotomy, diabetic retinopathy
and glaucoma, diseases primarily affecting the retinal gang-
lion cell neurons.19,20 We studied whether this mechanism is
functional in a disease primarily affecting photoreceptor
neurons, by quantifying the expression of p75NTR and proNGF
as well as the downstream effectors TNFα and α2M, and
the glial activation during the neurodegenerative process
associated with RP.
Expression of p75NTR in the rd10 and the RhoP retina. In
both wild-type (WT) and the dystrophic rd10 and RhoP
retinas, p75NTR immunostaining was mostly localized in
Müller glia cells, as shown in P21 retinal sections
(Figure 1). This observation was confirmed by costaining
with the Müller glial cell marker glutamine synthetase (GS;
Figure 1). Moreover, comparable p75NTR immunostaining
levels were found in both the WT and the dystrophic retinas.
Unprocessed proNGF and inflammatory markers are
increased in the rd10 retina. We analyzed gene expression
of the proNGF/p75NTR system components in the retina of the
rd10 mouse, in comparison with WT, starting at stages
previous to any observable sign of degeneration (P12) and
during the initial period of photoreceptor cell degeneration
and death, the time suited for a therapeutical treatment.
Quantitative RT-PCR analysis did not show significant
differences between WTand rd10 retinas in the mRNA levels
of either NGF, the p75NTR and Trk-A receptors, or the p75NTR
coreceptor sortilin, at P21, before the peak of photoreceptor
cell death but when the degenerative process is well
established (Figure 2a; WT expression level= 1). Indeed,
the mRNA profiles between P12 and P21 showed minor, no
significant differences between WT and rd10 retinas
(Supplementary Figure 1). In contrast, the mRNA levels of
the proinflammatory cytokines IL-1β and TNFα, as well as
that of the neurodegeneration-associated, secreted protein,
α2M were highly expressed at P21 in the rd10 retina
(Figure 2b; WT expression level=1). Moreover, a marked
reactive gliosis in the rd10 retina at this age was revealed by
the increase of GFAP mRNA, whereas CRALBP, a general
Müller glia cell transcript, remained unchanged with respect
to WT retina (Figure 2b). GFAP and α2M overexpression was
confirmed by immunolabeling of P21 retinal sections. The
increased expression of GFAP and α2M was observed in
both the rd10 and the RhoP retinas (Figure 2c). GFAP
immunoreactivity was associated to Müller gliosis, whereas
α2M immunoreactivity was localized in the most external part
of the dystrophic retinas, in close contact with the
photoreceptor segments, retinal pigmented epithelium and
choroids (Figure 2c and Supplementary Figure 2).
All these inflammatory signs concur with a marked increase
of microglial cells in the rd10 retina, determined at P23
(Figures 2d–f). Particularly relevant was the observed micro-
glial infiltration in the surroundings of the degenerating rd10
photoreceptor cells, including the outer plexiform layer, the
ONL and the outer segments of photoreceptors, where α2M
immunolabeling was localized.
Next, we examined the persistence of unprocessed proNGF
in the rd10 retina (Figure 3). The levels of proNGF, as
determined by ELISA, were similar in both theWTand the rd10
retinas at P13, before any detectable photoreceptor degen-
eration. Strikingly, proNGF protein significantly increased in
the rd10 retina at P18, an early degenerative stage close to the
beginning of photoreceptor cell death. ProNGF levels
remained elevated in the rd10 retina for the rest of the
analyzed period, covering the interval of major photoreceptor
cell loss, while proNGF in WT retinas persisted at similar,
relatively low levels throughout the same time period
(Figure 3a). Interestingly, a parallel determination of pro-
cessed NGF did not show any increase in the rd10 retina
(Figure 3b).
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Figure 1 p75NTR and GS immunostaining in the WT, rd10 and RhoP retinas.
Representative images of P21 retinal sections stained for p75NTR (green) and GS
(red). Nuclei are stained with DAPI. Scale bar: 20 μm. ONL, outer nuclear layer; INL,
inner nuclear layer; GCL, ganglion cell layer.
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These results suggest that elevated proNGF protein levels,
likely activating p75NTR in Müller glia cells, may have a role in
the pathogenesis of RP.
Blocking of p75NTR decreases photoreceptor cell death
and reactive gliosis in cultured rd10 retinas. We initially
tested three small-molecule antagonists of p75NTR 20 in
organotypic rd10 retinal explants from P22 mice (Figure 4).
Retinal explants recapitulate RP-associated photoreceptor
cell death seen in vivo and allow for an easier primary
screening before in vivo testing.25 In controls, very scarce
photoreceptor cell death is observed in the time frame of the
experiment in organotypic retinal explants from P22 WT mice
(data not shown).
THX-B (1,3-diisopropyl-1-[2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-
tetrahydro-purin-7-yl)-acetyl]-urea) was very effective and
reduced by 60% the density of TUNEL-positive nuclei in the
photoreceptor layer of treated rd10 retinas compared with
vehicle-treated rd10 retinas (Figure 4b). THX-A and THX-C
(also known as LM11A-2426) are less active small-molecule
analogs of THX-B, and exhibited a trend to reducing photo-
receptor death. Another p75NTR antagonist LM11A-3126 also
partially reduced the density of TUNEL-positive nuclei in the
retinal explants (Supplementary Figure 3a).
In these experiments, THX-B had the highest relative
potency in decreasing photoreceptor cell death; hence,
THX-B was selected for a more detailed characterization of
its effect ex vivo and in vivo. THX-B treatment of cultured P22
rd10 retinas attenuated the thickening and enlargement of
processes of astrocytes and Müller glia cells visualized by
GFAP immunostaining (Figure 5).
In vivo blocking of p75NTR preserves the ONL. The results
obtained in organotypic rd10 retinal explants suggest that
p75NTR may be a pharmacological target for RP. Hence, we
studied the in vivo effect of THX-B in the progression of the
retinal degeneration in the murine RP models. A single
intravitreal injection of THX-B at P17 in the rd10 mouse eye
elicited a neuroprotective effect on photoreceptor cells,
observable at P22. The number of photoreceptor rows as
well as the ONL/INL ratio were significantly higher in the
treated eye than in the vehicle-injected eye from the same
animal (Figures 6a–c). This concurred with a significant
decrease in the total number of microglial cells in the treated
retinas (Figure 6d), as well as a reduction in some of the
inflammatory signs, such as the mRNA levels of GFAP, α2M
and the proinflammatory cytokines IL-1β and TNFα
(Figure 6e; untreated retinas expression level= 1). Moreover,
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Figure 2 Expression of the NGF system components and inflammation markers. (a and b) RT-qPCR of WTand rd10 retinas at P21. The levels of the different transcripts were
normalized to the TBP RNA levels and relativized to WT levels (= 1). (c) Representative images of P21 retinal sections from WT, rd10 and RhoP mice, immunostained for glial
fibrillary acidic protein (GFAP) (cyan) and α2M (green). Nuclei are stained with DAPI. (d) Representative confocal images at the level of the photoreceptor segments, in P23 WT
and rd10 retinas immunostained for CD11b. (e) Magnification of inset from the rd10 retina. (f) Quantification of the number of CD11b-positive cells in the different layers of the WT
(gray bars) and rd10 (black bars) retinas. Bars represent the mean± S.E.M.; n≥ 3; **Po0.01, ***Po0.001. OS, outer segment; ONL, outer nuclear layer; ONL, outer nuclear
layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bars: (c) 30 μm; (d) 50 μm and (e) 20 μm
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these effects concur with the reduced levels of TNFα
secreted into the culture medium by LM11A-31-treated rd10
retinal explants (Supplementary Figure 3c), supporting the
proinflammatory role of p75NTR in RP.
Taken together, our observations support the involvement of
p75NTR in the molecular and cellular processes occurring in
the dystrophic retina and leading to degeneration.
To check the generality of our observations, we treated the
RhoP mouse, which presents photoreceptor cell loss with a
pace comparable to that of the rd10mouse,8 as well as similar
features concerning, at least, p75NTR, GFAP and α2M
expression patterns (Figures 1 and 2c). We first confirmed
the effect of THX-B on photoreceptor cell death in P18
organotypic RhoP retinal explants. As in the case of the rd10
retinas, THX-B significantly reduced the number of TUNEL-
positive photoreceptor nuclei in comparison with untreated
retinas (Figure 7a). We then tested the effect of THX-B in vivo
in two different ways. A single THX-B intravitreal injection at
P17 resulted, after 5 days, in higher ONL/INL thickness ratio
than that of the contralateral vehicle-injected eye (Figures 7b
and c), as previously shown for the rd10 mouse (Figures
6a–c). Although intravitreal injection is a common clinical
practice in human patients, we tested a less invasive delivery
method. The RhoP mice were treated with a single sub-
conjunctival injection of THX-B at P18 and the retinas were
analyzed at P22. Again, the eyes treated with THX-B
presented significant photoreceptor cell preservation as
determined by the observed higher density of photoreceptor
nuclei in the THX-B-treated eye than in the control eye
(Figures 7d and e).
Altogether, our results confirm that p75NTR has a relevant
role in the RP-associated degenerative process, and consti-
tutes a relevant therapeutic target to attenuate the course of
this incurable group of inherited retinal dystrophies.
Discussion
In the present work, we have analyzed the possible involve-
ment of proNGF/p75NTR signaling in the photoreceptor
degeneration process associated with RP. Moreover, we have
shown the potential therapeutic value of p75NTR antagonists
for RP treatment. THX-B administration reduced photorecep-
tor cell death ex vivo and in vivo, in two different RP models,
thus providing an initial proof of concept on a possible therapy
for RP. Remarkably, subconjunctival administration arises as a
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Figure 3 Precursor (proNGF) and processed protein (NGF) levels in the WTand
rd10 retinas. (a) ProNGF was quantified by enzyme-linked immunosorbent assay
(ELISA) in four retina pools, at the indicated ages. (b) NGF was quantified by ELISA in
four retina pools (the contralateral ones, from the same animals than proNGF) at the
indicated ages. Two-way analysis of variance (ANOVA) for proNGF, F= 12.99,
P= 0.0227; two-way ANOVA for NGF, F= 1.49, P= 0.2890
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Figure 4 Effect of p75NTR antagonists in rd10 retinal explants. P22 rd10 retinas were cultured for 24 h in the absence (vehicle) or presence of three different p75NTR
antagonists. (a) Representative images of retina explants stained for the TUNEL assay. (b) Quantification of the number of TUNEL-positive cells in the photoreceptor layer.
Bars represent the mean±S.E.M.; n≥ 3; *Po0.05, **Po0.01. Scale bar: 20 μm
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medical plausible treatment for RP, as well as for other retinal
dystrophies.27
The proneurotophin–p75NTR axis is emerging as a key
player in the progression of several neurodegenerative
pathologies.18 In the present study we have seen an increase
in the proNGF protein levels in the rd10 retinas before the
massive loss of photoreceptors while no significant changes
were observed in the processed NGF. Moreover, blocking
p75NTR decreased photoreceptor loss. Several studies in
models of retinal and brain neurodegenerative damage
showed a coordinated upregulation of several components
of the proNGF-p75NTR system.28,29 In this study, we did not
observe changes in the gene expression levels of NGF, Trk-A,
p75NTR or its coreceptor sortilin. Indeed, the p75NTR immu-
nostaining pattern is similar in the WT, rd10 and RhoP retinas,
besides those associated with the degenerative changes. The
nature of the damage aswell as the age at which degeneration
occurs may account for the differential regulation of the
proNGF-p75NTR system components in our model. In the rd10
mouse, a model of early onset RP, the increase in proNGF at
the protein level may be sufficient to trigger the neurotoxic
response through p75NTR. In addition, p75NTR may also bind
other proneurotrophins18 (namely pro-BDNF, pro-NT3) in the
degenerating rd10 retinas, an alternative that will be
addressed in future studies. The mechanistic role of the
proNGF-p75NTR signaling in neurodegenerative diseases has
been widely attributed to its proapoptotic action. Indeed,
p75NTR belongs to the tumor necrosis factor superfamily
characterized by the presence of an intracellular ‘death
domain’ that interacts with components of the program cell
death machinery.30 However, recent studies in retina have
shown the contribution of proNGF-p75NTR signaling to
neuronal death through a non-cell-autonomous, paracrine
mechanism. ProNGF acting on its p75NTR receptor in Müller
glial cells is able to induce TNFα production by Müller glial
cells, which provokes ganglion cell degeneration.23,31 We
have observed a selective location of p75NTR in Müller glial
cells inWT, rd10 andRhoP retinas (Figure 1) at the ageswhen
RP-associated photoreceptor degeneration is taking place.
The source of proNGF may vary according to the type of
injury and the affected tissue. It is worth recalling that
microglial cells are a potential source of proNGF in the retina
during development,32,33 as well as in models of retinal
dystrophies.34 In the rd10 retina, microglia is highly activated
and mobilized (Figures 2d–f), and may be the source of
proNGF.
ProNGF is efficiently processed in the uninjured adult
nervous system and very low levels of the proprotein form are
detected under physiological conditions. The intracellular
machinery that ensures the efficient conversion of proNGF
into mature NGF is not well characterized. Retinal degenera-
tion in the rd10 mouse was accompanied by an increase of
α2M, selectively located to the photoreceptor segment
ONL
INL
GCL
Vehicle THX-B
G
FA
P
G
FA
P 
D
A
PI
Vehicle THX-B
0
10
20
30
40
**
G
FA
P 
(%
 o
f t
ot
al
 a
re
a)
Figure 5 Effect of the p75NTR antagonist THX-B on reactive gliosis in rd10 retinal
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layer; GCL, ganglion cell layer
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Figure 6 In vivo effect of the p75NTR antagonist THX-B in the rd10 retina. P17
rd10 mice were intravitreally injected with THX-B in one eye and with vehicle in the
contralateral eye, and analyzed at P22. (a) Representative sections. Nuclei are
stained with DAPI. (b) Comparison of the photoreceptor number per row between the
THX-B-treated eye and the control eye. Paired eyes are individually represented.
(c) Comparison of the ONL/INL thickness ratio between the THX-B-treated eye and
the control eye. Paired eyes are individually represented. (d) Quantification of the
microglial (TL-positive) cell density in the THX-B treated retina versus the control
retina from the same animal. Paired eyes are individually represented. (e) RT-qPCR
of THX-B-treated and control retinas. The levels of the different transcripts were
normalized to the TBP RNA levels and relativized to control retina levels. Bars
represent mean±S.E.M.; n≥ 3; *Po0.05, **Po0.01; two-way analysis of variance
(ANOVA) for RT-qPCR of treated versus control retinas, F= 4.40, P= 0.0467. Scale
bar: 20 μm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear
layer; TL, tomato lectin
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(Figures 2b and c and Supplementary Figure 2) and
presumptively expressed by Müller glia cells,35 whose role in
retinal neurodegeneration has been recently characterized in
detail.22,24 α2M binds to proNGF conferring resistance to
processing and increased activity on p75NTR. The marked
increase in the α2M in the rd10 retina may account, at least in
part, for the accumulation of proNGF. On the other hand, α2M
binds to NGF and decreases its activity on the Trk-A receptor.
A hallmark of most forms of RP, despite their genetic origin,
is the primary death of rod photoreceptors, in which the
mutated gene exerts its function, followed by a secondary loss
of cone photoreceptors.5 Photoreceptor degeneration is
accompanied and followed by whole retinal remodeling,
including retinal pigmented epithelium disorganization, inner
neuronal connectivity alterations and vascular disorganization
and regression. Concomitant to these alterations an inflam-
matory process takes place as shown by microglial recruit-
ment, reactive gliosis of Müller glial cells and astrocytes, and a
burst of proinflammatory cytokine expression.3 The hierar-
chies, respective roles and molecular action of microglia,
Müller cells and astrocytes during rd10 retinal degeneration
remain to be elucidated. Interfering with one or several of these
common players may provide a general therapy, despite the
broad mutation spectrum of RP. Supporting this approach,
suppression of microglial activation by minocycline treatment
protected retinal structure and visual function in the rd10
mouse.14 Further, TNFα inhibition by Adalimumab in the rd10
mouse reduces photoreceptor cell death.16
In the present study, we have extended to RP the
therapeutic potential of interfering with the proNGF/p75NTR
system described for other retinal dystrophies.20,21,31
Materials and Methods
Animal procedures. The rd10 mouse model of retinal degeneration is a
homozygous recessive mutant for phosphodiesterase 6b (Pde6brd10/rd10) on a
C57BL/6 J background. The RhoP mouse model of retinal degeneration is a
hemizygous dominant mutant that carries the mutant human rhodopsin Pro347Ser
transgene on a C57BL/6 J background. WT mice of the same background were
used as control. All animals were housed and handled in accordance with the ARVO
statement for the Use of Animals in Ophthalmic and Vision Research, and
European Union and Canadian guidelines. Mice were bred in the CIB and Lady
Davis Institute core facilities.
Intravitreal injections. Rd10 and RhoP mice at P17 were anesthetized with
isoflurane. Intravitreal injection was performed under an ophthalmoscope to
visualize the retinal fundus. Using a Hamilton syringe (Hamilton AG, Bonaduz,
Switzerland; Model 75 RN SYR) with a 33-gauge removable needle, the right eye
was injected with 2 μl of the p75NTR antagonist, THX-B (2 μg/μl in 10% (v/v) DMSO
in PBS), whereas the left eyes received 2 μl of the vehicle. Animals were killed
5 days after injection, and eyes were processed for cryosectioning as described
below. Both male and female mice were used for this study and at least three
animals per group were used.
Subconjunctival injection. RhoP at P18 were anesthetized with isoflurane.
The conjunctiva was gently pulled from the sclera using tweezers. The conjunctiva
of the right eye was injected with 30 μl containing a total of 15 μg THX-B (0.5 μg/μl
in 10% (v/v) DMSO in PBS). Half of the total volume of THX-B was delivered into
the superior subconjunctival space and the other half into the nasal subconjunctival
region using a microsyringe with a 33 G needle. The left eyes received 30 μl of the
vehicle. Animals were killed 4 days after injection and processed as above.
p75NTR antagonists synthesis. THX-B and the analogs have been
described20 (US20100392647P patent by H Nedev and HU Saragovi). All
compounds were purified by HPLC to 499%. The empirical formula of THX-B
(F.W. 365) was confirmed by LC/MS, and the 1H NMR spectra (300 MHz) of
compounds are consistent with the expected structures.
Retina explant cultures. P20 and P22 rd10 and P18 RhoP mice were killed,
and their eyes were enucleated. Retinas were dissected and cultured free floating in
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Figure 7 Effect of the P75NTR antagonist THX-B, both ex vivo and in vivo, in theRhoP retina. (a) P18 RhoP retinas were cultured for 24 h in the absence (vehicle) or presence of
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contralateral eye, and analyzed at P22. Nuclei in whole-mount retinas were counterstained with DAPI. Representative cryosections. (c) Comparison of the ONL/INL thickness ratio
between the THX-B-treated eye and the vehicle control eye. Paired eyes are individually represented. (d) P18RhoPmice were subconjunctivally injected with THX-B in one eye and
with vehicle in the contralateral eye and analyzed at P24. Representative cryosections stained with toluidine. (e) Comparison of the density of nuclei in the ONL between the THX-B-
treated eye and the vehicle control eye. Paired eyes are individually represented. Bars represent the mean±S.E.M.; n≥ 3; **Po0.01; *** Po0.001. Scale bar: 20 μm. GCL,
ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer
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M24 multiwell plates for 24 h in 1 ml DMEM/F12 medium containing N2 supplement,
except insulin, and in the presence of the indicated p75NTR antagonist THX-A,
THX-B, THX-C, LM11A-31 (Tocris, Avonmouth, Bristol, UK), or vehicle. A dose
range of 0.2–40 μM drug concentrations were tested (only 20 μM shown). Retinas
were subsequently fixed in 4% (wt/vol) paraformaldehyde in phosphate buffer 0.1M,
pH 7.4, for 1 h at RT and processed for detection of cell death and immunostaining.
Cell death visualization and counting. Photoreceptor cell death was
visualized by DNA fragmentation using the TUNEL assay (DeadEnd Fluorometric
TUNEL System; Promega, Madison, WI, USA). Fixed whole-mount retinas were
permeated with 2% (wt/vol) Triton X-100 (Merck, Darmstadt, Germany) in PBS for
2 h at RT, followed by incubation in 20 μg/ml proteinase K (Merck) for 15 min at
37 °C and, subsequently, processed for TUNEL staining according to the
manufacturer's instructions. After TUNEL labeling, the nuclei were counterstained
with 0.05% (wt/vol) propidium iodide (Merck) in PBS, and the retinas were flat
mounted in Fluoromount-G (Southern Biotechnology, Birmingham, AL, USA), and
analyzed with a laser confocal microscope (TCS SP2; Leica Microsystems, Wetzlar,
Germany). Serial optical sections were acquired with the × 63 objective every 1 μm,
covering the whole ONL thickness in four central fields around the optic nerve.
Direct counting of TUNEL-positive cells was carried out using the FIJI
open-source Software.36
Immunolabeling of whole-mount retinas. Fixed whole-mount retinas
were permeated with 2% (wt/vol) Triton X-100 in PBS, blocked in BGT (2.5%
(wt/vol) BSA, 100 mM glycine, 0.25% (wt/vol) Triton X-100 in PBS) and incubated
overnight at 4 °C, with the indicated primary antibodies or 2 h at RT with a
biotinylated probe, after washing with TBS. Retinas were then washed with PBS and
incubated for 2 h at RT with the secondary antibodies or streptavidin. The nuclei
were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher
Scientific, Waltham, MA USA), the retinas were mounted in Fluoromount-G and
analyzed with a laser confocal microscope (TCS SP5 and TCS SP2; Leica
Microsystems). Antibodies are listed below.
For determining microglia density, serial optical sections were acquired with a × 40
objective every 2.5 μm through the whole retina in four central fields around the optic
nerve. To measure the percentage of the area occupied by GFAP staining, serial
optical sections were acquired with a × 40 objective every 2 μm, covering the whole
ganglion cell layer in 12 fields (four central, four medial and four peripheral) around
the optic nerve. Confocal maxima of the ganglion cell layer Z sections were then
converted into a black and white image and analyzed with the FIJI Software to
calculate the percentage of total area filled with GFAP.
Immunostaining of retinal sections. Animals were killed, their eyes were
enucleated, fixed for 1 h in 4% (wt/vol) parafolmaldehyde in phosphate buffer 0.1 M,
pH 7.4, and then cryoprotected by incubation in increasing concentrations of
sucrose (15–50% in PBS). The eyes were then embedded in Tissue-Tek (Sakura,
Leiden, The Netherlands), and frozen on dry ice. Cryostat sections (12 μm) were
mounted on Superfrost slides (Thermo Fisher Scientific) and dried at room
temperature. For p75NTR immunostaining, retinal sections were rehydrated in PBS,
incubated with NaBH4 5 mg/ml in PBS for 5 min, followed by 0.1% (wt/vol) Triton
X-100 and 5% (v/v) normal goat serum in PBS for 1 h. For immunostaining with the
rest of the antibodies, retinal sections were permeated for 1 h with 0.2% (wt/vol)
Triton X-100, and blocked with BGT for another hour. Following the incubation with
the primary antibody overnight at 4 °C, the sections were washed with PBS and
incubated for 1 h with secondary antibodies and DAPI. Then, sections were washed
with PBS and coverslipped with Fluoromont-G. Antibodies are listed below.
To quantify the retinal structure using techniques unbiased to retinal location (i.e.
the central regions of the retina are thicker than the peripheral regions), we compared
the thickness of the ONL (containing primarily photoreceptors) and the corresponding
INL (containing bipolar, horizontal and amacrine neuron as well as Müller glia cell
bodies). Both ONL and INL were measured, and the ONL/INL ratios were calculated
in treated eyes versus vehicle-injected contralateral eyes. Five sections per retina
were analyzed. For each section, one photograph was taken for each of four defined
retinal zones. In each photo three measurements of the ONL and INL thickness were
performed in triplicate to obtain an average value per retinal zone per section. The
measurements were carried out with the FIJI Software (using the ‘freehand line’ and
‘measure’ tools). Alternatively, the number of nucleus rows or the nuclear density in a
determined retinal area were quantified in the same way to corroborate the
neuroprotective effect and the accuracy of the ONL/INL ratio determination.
Antibody Host
species
Dilution Manufacturer
α2M Rabbit 1 : 100 Santa Cruz, Dallas, TX, USA
Cd11b Rat 1 : 200 Abcam, Cambridge, UK
GFAP Rabbit 1 : 250 Dako, Glostrup, Denmark
GS Mouse 1 : 200 Merck, Darmstadt, Germany
P75NTR Mouse 1 : 200 Abcam, Cambridge, UK
Tomato
lectin (TL)
— 1 : 200 Sigma-Aldrich, Saint Louis,
MO, USA
Alexa 488–
546–647
Streptavidin
488
Goat
—
1 : 200–500
1 : 400
Thermo Fisher Scientific,
Waltham, MA, USA
ProNGF, NGF and TNFα levels determination. ProNGF and NGF levels
were measured in retinal extracts from the same animals by ELISA assay
(MyBioSource Inc., San Diego, CA, USA). For proNGF determination, four retinas
per age were homogenized in PBS at 100 mg wet weight per ml and stored
overnight at − 20 °C. After two freeze–thaw cycles, the homogenates were
centrifuged for 5000xg at 4 °C for 5 min. The supernatant was removed and assayed
immediately following the manufacturer’s instructions. For NGF determination, the
four contralateral retinas per age of the same animal used for proNGF determination
were homogenized in PBS at 100 mg wet weight per ml and centrifuged for 1500xg
for 15 min. The supernatant was removed and assayed immediately. TNFα
concentration was measured in culture supernatant from retinal explants by ELISA
assay (BioLegend, San Diego, CA, USA) following the manufacturer’s instructions.
RNA isolation and quantitative PCR. Total RNA from individual retinas was
extracted using the TRIzol reagent, and 2.5 μg of RNA were typically reverse transcribed
(RT) using the Superscript III Kit and random primers (all from Thermo Fisher Scientific).
Quantitative PCR (qPCR) was performed with the ABI Prism 7900HT Sequence
Detection System using TaqMan Universal PCR Master Mix, No-AmpErase UNG and
the Taqman assays (listed below) for detection (all from Thermo Fisher).
Gene Taqman assay
Ngf Mm00443039_m1
Trk-a Mm01219406_m1
P75ntr Mm01309638_m1
Sortilin Mm00490905_m1
Tnfα Mm00443260_g1
IL1β Mm00434228_m1
A2M Mm00558642_m1
Gfap Mm01253033_m1
Cralbp Mm00445129_m1
Tbp Mm00446971_m1
Statistical analysis. Data size was estimated in accordance with previous
literature, following the Reduction principle for animal research. At least three
animals were analyzed per experimental point. Data points in graphs represent
individual mice, and bars in all panels represent the mean and the standard error of
the mean (S.E.M.).
Data were checked for normality using both D’Agostino–Pearson omnibus and
Kolmogorov–Smirnov normality tests sequentially. Data were considered to fit a
normal distribution only if they passed simultaneously both tests. For normal data,
Fisher’s test was used to determine whether the variance of the samples analyzed
was comparable (homoscedasticity). Normal data were compared using a two-way
ANOVA with Bonferroni's multiple comparison test or an unpaired Student’s T-test,
applying Welch’s correction in cases of non-homoscedasticity. In cases of non-normal
samples, populations were compared using the Mann–Whitney nonparametric U-test.
Outliers were detected by Grubbs’ outlier test, and excluded from further analysis. If
previous literature allowed us to make a prediction about the result of the experiment,
then one-sided test were applied. Otherwise, tests were two sided. All analyses were
performed at a fixed 95% confidence interval, using the GraphPad Prism version 5.01
for Windows (GraphPad Software, San Diego, CA, USA; http://www.graphpad.com).
Statistically significant differences are indicated as follows: *Po0.05; **Po0.01;
***Po0.001.
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